Andrzej Jakubowiak, MD, PhD

Andrzej Jakubowiak, MD, PhD, discusses efficacy data with maintenance KRd after ASCT in multiple myeloma.

Andrzej Jakubowiak, MD, PhD, discusses the design of the phase 3 ATLAS trial in patients with newly diagnosed multiple myeloma after ASCT.

Andrzej Jakubowiak, MD, PhD, discusses how the data from the PERSEUS Study informed the ATLAS trial in multiple myeloma.

Andrzej Jakubowiak, MD, PhD, discusses the rationale of the phase 3 ATLAS study in patients with multiple myeloma.

Andrzej Jakubowiak, MD, PhD, discusses initial efficacy results from the phase 3 ATLAS trial in multiple myeloma.

Andrzej Jakubowiak, MD, PhD, professor of medicine, director, Myeloma Program, The University of Chicago Medicine, discusses a phase I study of daratumumab (Darzalex) in combination with carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (KRd) in patients with newly diagnosed multiple myeloma.

Andrzej Jakubowiak, MD, PhD, professor of Medicine, director, Myeloma Program, University of Chicago Medicine, discusses minimal residual disease in multiple myeloma.

Andrzej Jakubowiak, MD, PhD, professor of Medicine, director, Myeloma Program, University of Chicago Medicine, discusses the likelihood of finding a cure for patients with multiple myeloma.

Andrzej Jakubowiak, MD, PhD, professor of medicine, director, Myeloma Program, University of Chicago Medicine, discusses the current and future state of multiple myeloma treatmen

Andrzej Jakubowiak, MD, PhD, professor of medicine, director, Myeloma Program, University of Chicago Medicine, discusses the toxicity profile of panobinostat in combination with bortezomib and dexamethasone in relapsed or relapsed/refractory multiple myeloma as seen in the PANORAMA trial.